Tecfidera (dimethyl fumarate): Updated recommendations in the light of cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Tecfidera
Active substance
dimethyl fumarate
Therapeutic area (MeSH)
Multiple Sclerosis
Procedure number
EMEA/H/C/002601/II/0063
Regulatory outcome
Variation
DHPC type
Type II variation
Human ATC code
L04AX07
Dissemination date
12/11/2020

How useful was this page?

Add your rating